Sustanon 250 is a prescription testosterone medicine containing four testosterone esters in an oil solution. The current United Kingdom product record lists testosterone propionate, phenylpropionate, isocaproate and decanoate. The esters are converted to testosterone after release into the circulation. Their different durations do not create four separate anabolic drugs or make the blend safer for nonmedical use.
Evidence boundary: a regulated medicine label can establish composition, licensed use, warnings and known adverse reactions for that product in its stated jurisdiction. It cannot verify an unregulated vial, support a bodybuilding cycle, predict an individual result or remove cardiovascular, blood, fertility, mood and injection related risks.
Medicine, regulatory and sport doping sources checked 4 September 2026. This page provides general evidence, not a diagnosis, prescription, cycle, injection method, purchase route or drug testing strategy.
What is Sustanon?
Sustanon is a brand name used for injectable testosterone mixtures. The best documented current product is Sustanon 250, a prescription solution that combines four esterified forms of testosterone. The number 250 refers to the combined mass of the four testosterone esters in one millilitre of the United Kingdom product. The same label states that this corresponds to 176 mg of testosterone after accounting for the ester groups.[1]
Testosterone is the active hormone released after the ester bonds are hydrolysed. It acts through androgen receptors and can also be converted to dihydrotestosterone and estradiol. Those pathways help explain changes in sexual function, muscle, bone, red blood cell production, skin, prostate tissue and fluid balance. They also explain why a testosterone blend can produce estrogenic, androgenic and blood related adverse effects.
Terms such as “Sustanon 250,” “Sustanon 300” and “Sustanon 400” are not interchangeable evidence records. A regulated label defines one product in one jurisdiction. A higher number printed on an unregulated vial does not establish its ingredients, concentration, sterility or origin.
| Drug class | Testosterone medicine; androgen and anabolic androgenic steroid. |
|---|---|
| Documented formulation | Oil based solution containing four testosterone esters. |
| Licensed UK use | Testosterone replacement for male hypogonadism confirmed by clinical features and biochemical tests. |
| Irish product record | The HPRA record for Sustanon 250 ampoules shows the licence as withdrawn on 4 December 2008. |
| Main evidence limit | Medical product evidence does not establish a safe nonmedical exposure or the contents of an unregulated product. |
| Competitive sport | Testosterone and its esters are prohibited at all times under the 2026 WADA Prohibited List. |
Which testosterone esters are in Sustanon 250?
The United Kingdom product record lists four active substances. Each is testosterone joined to a different ester group. Esterification affects release from the injection depot and the time course before testosterone becomes available. It does not change the final active hormone into a new compound.
| Ester | Amount per 1 ml ampoule | What the name establishes | What it cannot establish |
|---|---|---|---|
| Testosterone propionate | 30 mg | A defined esterified form of testosterone | A personal response or safe nonmedical use |
| Testosterone phenylpropionate | 60 mg | A second esterified form in the blend | Purity of a vial outside the regulated supply chain |
| Testosterone isocaproate | 60 mg | A distinct ester group with its own release properties | An exact release curve for every person |
| Testosterone decanoate | 100 mg | The largest ester mass in this formulation | A safer profile, better result or verified concentration |
The four ester amounts total 250 mg, while the label reports 176 mg of testosterone per millilitre. The difference reflects the mass of the attached ester groups. Comparing a testosterone equivalent amount with a total ester mass without this distinction can create a false comparison.
Is Sustanon a licensed medicine?
Status depends on country, product and date. The United Kingdom electronic Medicines Compendium carries a Sustanon 250 product record revised in December 2025. It identifies Aspen Pharma Trading Limited as the marketing authorisation holder and lists testosterone replacement for confirmed male hypogonadism as the main therapeutic indication.[1]
Aspen Pharmacare Australia also lists Sustanon 250 and links to Australian regulator hosted product information. In Ireland, the HPRA record for Organon’s Sustanon 250 ampoules reports that licence PA0261/009/003 was withdrawn on 4 December 2008.[3] A withdrawn Irish licence does not prove that every Sustanon labelled product is unlawful everywhere, unsafe because of the withdrawal, or currently authorised in Ireland. Those are separate regulatory questions.
The medical indication is not a bodybuilding indication. The UK label requires clinical features and biochemical confirmation of testosterone deficiency. A brand’s medicine history cannot be used as proof that supraphysiological exposure in a person with normal gonadal function has a favourable balance of benefit and risk.
What effects can Sustanon produce?
In men with confirmed hypogonadism, the product record describes a rise in testosterone and related hormones, improvement in testosterone deficiency symptoms, increased bone mineral density and lean body mass, reduced fat mass, and improved libido and erectile function. It also records increases in haemoglobin and haematocrit, changes in lipids, water retention and possible prostate growth.[1]
Those findings describe treatment of a diagnosed deficiency. They do not predict the size, speed or durability of physique and performance changes in people using testosterone outside medical care. Baseline hormone status, exposure, training, nutrition, age, genetics, health conditions, other drugs and product identity all affect outcomes.
The ester mixture changes the delivery profile, not the basic androgen receptor pathway. Once released, testosterone can influence many tissues at the same time. A visible change in muscle or body weight cannot show what is happening to blood pressure, haematocrit, lipids, fertility, mood, sleep or cardiac structure.
What Does Sustanon Do? covers effects in a narrower way. This compound overview keeps those effects in context with identity, medical status, health risks, law and sport rules.
How strong is the evidence for common Sustanon claims?
| Claim | Best evidence | Confidence | Limit |
|---|---|---|---|
| Sustanon 250 contains four named testosterone esters | Current regulated product information | High for the labelled UK medicine | Does not verify an unregulated vial |
| The blend treats confirmed testosterone deficiency | Licensed indication and clinical testosterone evidence | High for the stated patient group | Does not create a nonmedical indication |
| Different esters provide different release durations | Pharmacokinetic product data | High for the regulated formulation | Individual timing still varies |
| Sustanon is superior to every single ester testosterone | No universal direct comparison evidence for all outcomes | Unsupported as a general claim | Choice depends on indication, product access and clinical assessment |
| Cycling or stacking prevents harm | Public health and anabolic steroid evidence | No evidence of risk removal | Multiple exposures can add risk and obscure causation |
| A normal blood result proves safety | Product warnings and broader clinical evidence | Unsupported | No single test clears every organ system or future risk |
What health risks are associated with Sustanon?
| Risk group | What the evidence supports |
|---|---|
| Blood and circulation | Testosterone can raise haemoglobin, haematocrit and red blood cell count. Polycythaemia, higher blood pressure, fluid retention and thrombotic events are recognised concerns, especially when other risk factors are present. |
| Heart, kidneys and liver | Fluid retention can worsen cardiac, kidney or liver insufficiency. The product record calls for caution in ischaemic heart disease and monitoring of liver function and lipids during long term androgen treatment. |
| Hormones and fertility | External testosterone can suppress sperm production and impair fertility. Gynaecomastia, altered libido, ejaculation problems, testicular changes and recovery uncertainty may occur. |
| Mood and dependence | Reported androgen related effects include depression, nervousness, mood change and altered libido. Testosterone misuse can lead to dependence and withdrawal symptoms. |
| Skin, hair and prostate | Acne, itching, scalp hair loss in susceptible people, prostate growth and raised PSA may occur. Known or suspected prostate or breast carcinoma is listed among the contraindications. |
| Injection and allergy | Local reactions, infection and tissue injury are possible with injections. The regulated UK product contains refined arachis oil and benzyl alcohol; peanut or soya allergy is a labelled contraindication. |
The medical label notes that adverse effects cannot be reversed at once simply by stopping an injectable depot product. Nonmedical exposure adds uncertainty about dose, sterility, solvents, concentration and combined substances. Read the broader anabolic steroid health risk overview for organ system warning signs and evidence limits.
Which medicines and health conditions need extra care?
A prescriber needs a complete list of medicines, supplements and other drug exposures. The Sustanon 250 record describes clinically relevant interactions and contexts that can change assessment.
| Medicine or context | Why it needs review | Possible clinical response |
|---|---|---|
| Coumarin anticoagulants | Androgens can enhance anticoagulant action | Closer clotting assessment and clinician led medicine review |
| Insulin and diabetes medicines | Androgens may improve glucose tolerance and change medicine needs | Glucose review during treatment changes |
| SGLT-2 inhibitors | A cumulative rise in haematocrit is possible | Haemoglobin and haematocrit assessment |
| ACTH or corticosteroids | Combined exposure may increase oedema | Extra caution with cardiac, liver or oedema risk |
| Enzyme inducers or inhibitors | Testosterone concentrations may change | Prescriber review based on the medicine involved |
| Thrombophilia or prior clot | Post marketing thrombotic events have been reported | Individual risk assessment before continuation |
Heart, liver or kidney insufficiency, hypertension, sleep apnoea, migraine, epilepsy, prostate symptoms, diabetes and a history of cardiovascular disease can alter the risk assessment. Pregnancy, breastfeeding, known or suspected prostate or breast carcinoma, and hypersensitivity to the ingredients are listed contraindications in the UK record.
What may clinicians monitor during prescribed treatment?
The UK product information calls for testosterone measurement before treatment and at intervals during care. It also names haemoglobin, haematocrit, prostate assessment and PSA, liver function and lipid profile among monitoring considerations. The timing and interpretation belong to the treating clinician because age, symptoms, medical history, formulation and medicine combination change what a result means.
Testing has limits. A normal testosterone result does not clear blood pressure, fertility, sleep, mood, cardiac structure or product sterility. A high haematocrit does not identify every contributing factor. Symptoms, physical assessment, exposure history and trends across related tests are often more informative than one isolated number.
What is Sustanon’s legal and sport doping status?
Medicine approval, possession law, supply law and sport prohibition are separate systems. In the United Kingdom, anabolic steroids are prescription only Class C drugs. NHS information states that possession for personal use is legal, while supply and several import or export routes are restricted.[5] United States federal law treats anabolic steroids, including testosterone, as Schedule III controlled substances.[6]
The Irish HPRA record cited here answers a product authorisation question: the listed Irish licence was withdrawn in 2008. It does not, by itself, answer every possession, prescription, import or supply question. Current advice for a personal case should come from a pharmacist, prescriber or jurisdiction qualified legal source.
The 2026 WADA Prohibited List names testosterone within S1.1 anabolic androgenic steroids and states that the class includes their esters. It is prohibited at all times, both in and out of competition.[4] A prescription does not automatically settle sport doping eligibility; an athlete needs advice under the rules governing their sport and any applicable therapeutic use exemption process.
Can a Sustanon label prove what is in a vial?
No. A brand style label, hologram, colour, batch code or claimed concentration cannot independently prove ingredients, strength, sterility or storage history. Regulated product information describes the authorised medicine, not every product using the same name online or in an informal market.
Unregulated products may contain the wrong ester, a different concentration, another anabolic agent, unsuitable oil, particulates or microbial contamination. Home test kits and visual inspection cannot provide a complete pharmaceutical quality assessment. New pain, spreading redness, heat, swelling, discharge, fever or feeling seriously unwell after an injection needs medical assessment.
How to assess Sustanon product claims safely
Sustanon is best approached as a named testosterone medicine, not as a guarantee that any vial, ampoule or online listing contains a regulated product. The name may refer to a licensed medicine in one setting, an older product record in another, or a product using a familiar label outside normal pharmacy supply. That distinction changes the health, legal and sport risk discussion.
The safest way to assess a Sustanon claim is to separate product identity, country, exposure context and health outcome. A medicine record can describe composition, indication, contraindications and adverse reactions for a named product. It cannot verify an informal market product, confirm sterility, predict a physique result or make nonmedical testosterone exposure safe.
| Question | Reliable evidence | Risk if skipped |
|---|---|---|
| Is this the regulated medicine? | Current product record from a regulator or official medicine compendium. | A label name may be treated as proof of contents without confirming identity. |
| What is the exposure context? | Prescriber record, pharmacy supply and clinical indication. | Medical replacement therapy may be confused with nonmedical exposure. |
| What outcome is promised? | Specific clinical endpoint or clear evidence limit. | Muscle, strength, libido and mood claims may be bundled together without proof. |
| What harms need checking? | Symptoms, examination and targeted clinical tests. | Visible improvement may hide blood pressure, blood count, fertility or mood changes. |
Common Sustanon misconceptions
A common mistake is to treat a blend as automatically smoother, safer or more balanced than a single testosterone ester. That assumption needs direct comparative evidence in the same population and outcome being discussed. A second mistake is to treat a medical indication as a performance indication. A third is to use old licence status from one country as a simple global legal answer.
The narrower and safer approach is to identify the medicine record, state the country and date, explain the active hormone and separate prescription use from nonmedical use. Side effects belong next to claimed effects because the same androgen exposure that changes strength, libido or mood can also affect blood pressure, blood counts, fertility, sleep, acne, hair loss, prostate symptoms and mental health.
Does a four ester blend mean four different effects?
No. The ester groups affect release timing. The active hormone released is testosterone, and the main risk discussion still belongs to testosterone exposure, dose, duration, health context and product certainty.
Can a blood test prove a Sustanon plan is safe?
No. Tests can reveal selected warning signals, but no single test clears blood pressure, fertility, mood, sleep, heart structure, sterility or future risk. Symptoms and exposure history still need review.
Does legal access in one country settle status elsewhere?
No. Medicine authorisation, controlled drug rules and sport rules vary by jurisdiction and change over time. A country specific regulator or legal source is needed for the setting being discussed.
Clinical care after Sustanon exposure
If a person has used a product labelled Sustanon, the most useful next step is a clear clinical history rather than a private dose adjustment. A clinician needs to know what was used, when it was used, how it was supplied, which symptoms appeared and which health conditions or medicines may change risk.
Assessment may include blood pressure, examination, blood count, liver and kidney markers, lipids, testosterone axis markers and symptom directed checks. The right tests depend on the person, the product uncertainty, the timing of exposure and any warning signs. Severe chest symptoms, fainting, one sided weakness, severe breathlessness, major allergic symptoms or serious injection reactions need urgent assessment.
| Information | Why it helps |
|---|---|
| Product name and photos | Helps separate a regulated medicine from a product using the name without verified supply. |
| Dates and route | Helps interpret symptoms, depot exposure and possible recovery timing. |
| Other drugs and supplements | Helps assess combined effects on blood, liver, mood, heart and glucose control. |
| Symptoms and measurements | Blood pressure readings, swelling, mood change, chest symptoms or injection reactions can alter urgency. |
References
- electronic Medicines Compendium: Sustanon 250 Summary of Product Characteristics. Text revised December 2025; checked 4 September 2026.
- electronic Medicines Compendium: Sustanon 250 Patient Information Leaflet. Checked 4 September 2026.
- Health Products Regulatory Authority: Sustanon 250 Ampoules. Irish licence record; checked 4 September 2026.
- World Anti Doping Agency: 2026 Prohibited List. Effective 1 January 2026; checked 4 September 2026.
- NHS: Anabolic steroid misuse. Checked 4 September 2026.
- United States Drug Enforcement Administration: Steroids. Checked 4 September 2026.
- Aspen Pharmacare Australia: Sustanon 250. Product information index; checked 4 September 2026.